Stable Angina, No Prior Infarct: Is a Beta-Blocker Still First
A single patient whose angina, and whose chart, both lack the one detail that used to make his first prescription an obvious choice. The disagreement is about whether a decades-old default deserves to keep making that choice for him.
T.N., a 61-year-old man, has taught the evening darkroom class at the community college for eighteen years, and switched most of his own personal photography work over to digital a few years back once his hands started giving him enough trouble with the developing trays that standing over them for long stretches stopped being worth it. He quit smoking ten years ago, after a health scare unrelated to his heart convinced him it was finally time, and has mild hyperlipidemia managed on a moderate-intensity statin. For the past several weeks, the two flights of stairs up to his classroom have started producing a predictable tightness across his chest, gone within a few minutes of resting at the top — never at rest, never lasting, always the same stairs.
Cardiac catheterization shows a moderate stenosis in his left circumflex artery, judged not to need revascularization, with no prior myocardial infarction and a preserved ejection fraction on echocardiogram. That last detail matters more than it might first appear: beta-blockers earned their place as default first-line therapy for angina largely from trials in patients who had already had an infarct or who had reduced heart function, populations where the mortality benefit is well established. In a patient like him — angina without either of those — more recent evidence hasn't shown the same mortality benefit from a beta-blocker specifically, which reopens a question that guideline habit has mostly treated as settled: does his first anti-anginal drug actually need to be a beta-blocker, or is that an inherited default rather than a conclusion drawn from data that actually includes patients like him.
Whether the default still applies
Beta-blocker first. It's the anti-anginal we default to for a reason — reliable symptom control, real rate control, and decades of comfort prescribing it in exactly this setting. I don't think we need to reinvent his first prescription because of a data nuance that's more about which trials existed than about whether the drug works for angina itself.
The nuance matters more than "which trials existed" suggests. The mortality benefit beta-blockers are famous for comes specifically from post-MI and reduced-EF populations — he's neither. For anginal symptom control alone, calcium channel blockers perform comparably, and his resting heart rate is already 68; adding a beta-blocker on top of that risks more fatigue and exercise limitation than a calcium channel blocker would, in a patient whose job has him on his feet demonstrating technique to a room of students most evenings.
I'm not saying beta-blockers don't work for his symptoms — they likely would. I'm saying "first-line by default" and "first-line because the evidence specifically supports it for him" are different claims, and only one of them is actually true here.
Both drug classes have real, comparable anti-anginal efficacy in a patient without a prior infarct or reduced ejection fraction — this isn't a case where one option is quietly worse. Given his resting heart rate already sits at 68 and his evenings involve standing and demonstrating for long stretches, a calcium channel blocker avoids compounding fatigue that a beta-blocker could plausibly add, without giving up anything in expected symptom control. I'd present both as legitimately equal options and let him weigh in, rather than starting either one because it's the default.
Amlodipine started as the first anti-anginal agent, following a direct conversation in which T.N. was told both options were genuinely comparable rather than one being deferred to habit; statin intensified, aspirin started, sublingual nitroglycerin supplied for as-needed use. The beta-blocker was held as the next step if symptoms persist, not presented as a fallback for a failed "real" first choice.
The disagreement over how strongly to default to a beta-blocker in patients like him was not fully resolved between the two cardiologists — decided in this instance by his own physiology and preference, not by either argument winning outright.